Search

El Pectus excavatum, es una malformación congénita de la pared anterior del tórax, caracterizada por una depresión del esternón. Objetivo: Evaluar los resultados del tratamiento quirúrgico en pacientes con pectus excavatum, utilizando la técnica de Nuss. Material y métodos: Diez pacientes con Pectus excavatum, de 6 a 22 años, operados, fueron incluidos. El seguimiento fue de 2 a 14 meses. Resultados: La edad promedio fue 11,5 años, ocho fueron varones, seis tuvieron pectus excavatum simétrico, el Índice de Haller promedio fue 5,1. La indicación de cirugía fue sintomatología broncopulmonar en 4, cuatro cardiológica, uno psicológico y otro recidiva de pectus Post-Ravitch. En todos los pacientes se implantó una barra metálica con dos estabilizadores, el tiempo operatorio fue entre 2 y 4 horas y la estancia hospitalaria, 7 días. Tres pacientes presentaron complicaciones postoperatorias: neumotórax en dos y en uno fijación inadecuada; en el seguimiento los pacientes no fueron asintomáticas y todos mostraron satisfacción con el tratamiento. Conclusiones: La técnica de Donald Nuss es un procedimiento que corrige el Pectus Excavatum, reduce el tiempo operatorio y estancia hospitalaria, con presentación de complicaciones menores y resultados clínico-psicológicos satisfactorios.(Rev Med Hered 2011;22:108-114).

Competing Interests: The authors report no conflict of interest.

Purpose: To compare brachytherapy (BT) boost of low-dose-rate (LDR) and high-dose-rate (HDR) techniques in patients diagnosed with intermediate-risk prostate cancer., Material and Methods: Between January 2005 and February 2018, 142 patients (50 LDR and 92 HDR) with intermediate-risk prostate cancer were treated with a BT boost, and retrospectively analyzed. Prescribed dose was 45 Gy with external beam radiotherapy (EBRT) plus 100-108 Gy with LDR-BT, and 60 Gy with EBRT plus one fraction of 10 Gy with HDR-BT. 99% of patients received androgen deprivation therapy (ADT) for 6 months. Primary endpoint was to compare LDR and HDR boosts in terms of biochemical progression-free survival (bPFS). Secondary endpoint, after re-classifying patients into "favorable" and "unfavorable" sub-groups, was to analyze differences with a similar treatment intensity., Results: Median overall follow-up for the total cohort was 66.5 months (range, 16-185 months). There were no significant differences in bPFS, overall survival, cause specific survival, local failure, lymph node failure, or distant failure when LDR or HDR was employed. bPFS at 90 months was 100% for favorable, and 89% and 85% for unfavorable patients at 60 months and 90 months, respectively (log-rank test, p = 0.017). The crude incidence of genitourinary acute and chronic toxicity grade 3 was 0.7% and 4%, respectively. Twelve patients (8%) had chronic rectal hemorrhage grade 2, in whom argon was applied (4 LDR and 8 HDR)., Conclusions: Combined treatment is an excellent therapeutic option in patients with intermediate-risk prostate carcinoma, with similar results in both LDR and HDR approaches and very low toxicities. Importantly, the current literature has indicated that unfavorable-risk patients belong to a different category, and should be treated as patients with high-risk factors. Therefore, the stratification and identification of both risk groups is extremely relevant., Competing Interests: The authors report no conflict of interest., (Copyright © 2021 Termedia.)

This project won the First Edition 2007 VAC Therapy Prize. This project tells the story of a woman suffering from lesions in her left leg and running a fever whose prognosis was complicated. The article describes the nurses' evaluation of the patient's lesions, skin sores, and the application of a treatment plan using nursing diagnoses and the satisfactory treatment with negative topical pressure.